Darvadstrocel for perianal fistulae is reimbursed by European national health systems (Spain, France, Germany, Italy) following conditional EU approval, typically with gastroenterology authorisation. Systemic MSC remission therapy is not reimbursed by any major insurance scheme; classified as investigational. US insurance does not cover either indication. Out-of-pocket payment is standard for non-fistula MSC therapy; fistula therapy may be partially covered in EU depending on national formulary inclusion and prior authorisation criteria.
Darvadstrocel for perianal fistulae costs approximately €7,000–9,500 per application in European centres. Systemic MSC induction therapy for active Crohn's or ulcerative colitis costs €6,000–8,000 per infusion protocol. Multiple fistulae or combined induction+maintenance regimens escalate costs to €12,000–20,000+ per year. Insurance coverage varies significantly: EU approved indication (perianal fistulae) is reimbursed by several national healthcare systems (Spain, France, Germany) with prior authorisation; systemic IBD remission therapy is rarely covered, classified as investigational. Out-of-pocket payment is standard for non-fistula indications.
Am I a candidate? → · Crohn's & IBD: full overview → · Crohn's & IBD cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment